Tennessee health care and public health leaders urge immediate action to protect state’s children from vaccine-preventable diseases
Measures proposed to address decline in adolescent vaccination associated with the COVID-19 pandemic
PREVNAR 20™
U.S. FDA APPROVES PREVNAR 20™, PFIZER’S PNEUMOCOCCAL 20-VALENT CONJUGATE VACCINE FOR ADULTS AGES 18 YEARS OR OLDER
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
